ACADIA issues press release on FDA Fast Track designation for remlifanserin in Alzheimer’s disease psychosis
ACAD•Development program updates
- RADIANT Phase 2 enrollment is complete; topline results expected in September to October 2026.
- Screening and enrollment are underway in the Phase 3 studies.
FDA grants Fast Track designation for remlifanserin
ACADIA Pharmaceuticals said the FDA granted Fast Track designation to remlifanserin for hallucinations and delusions in Alzheimer’s disease psychosis.
